Greenwich LifeSciences Expands GP2 Market Potential with New Patent Claims — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences filed new patent claims based on FLAMINGO-01 trial data, potentially doubling GP2 market potential to 88,000 new patients annually in the US and Europe.
Preliminary analysis shows an approximately 80% reduction in recurrence rates for non-HLA-A*02 patients treated with GLSI-100.
The company has started enrolling both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 based on FDA protocol changes.
If granted, the new patent claims could provide protection through 2045.

The big picture

Greenwich LifeSciences' new patent claims represent a strategic shift in the immunotherapy landscape, potentially expanding the addressable market for GP2. The company's ability to treat both HLA-A*02 and non-HLA-A*02 patients could position it as a leader in breast cancer recurrence prevention. This development comes amid growing interest in personalized immunotherapies and the need for more effective treatments for high-risk breast cancer patients.

What we're watching

Patent Approval Timeline: The pace at which the new patent claims are granted will determine the duration of market exclusivity for GP2.
Clinical Trial Results: Whether the preliminary 80% reduction in recurrence rates for non-HLA-A*02 patients holds up in final FLAMINGO-01 data.
Market Expansion Strategy: How Greenwich LifeSciences plans to capitalize on the potential doubling of the GP2 market to $10 billion in annual revenue.